Clinical trials: Tislelizumab
Hepatocellular Carcinoma (HCC)
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The goal of this interventional study (clinical trial) is to evaluate the efficacy and safety of adding dapagliflozin to first-line standard therapy in patients with unresectable hepatocellular carcinoma (HCC) and comorbid…
- Trial name
- NCT07729592
- Testing
- Dapagliflozin, Donafenib, Tislelizumab
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
This is a prospective, single-arm, multicenter phase II clinical study evaluating the efficacy and safety of spatially fractionated radiotherapy (SFRT) combined with tislelizumab and platinum-based doublet chemotherapy as…
- Trial name
- NCT07775040
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Immunotherapy Esophagus Cancer
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)
- Trial name
- NCT05515315
- Testing
- Tislelizumab, Albumin paclitaxel, Nedaplatin
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fuzhou General Hospital
Rare Tumour
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug…
- Trial name
- SPRING (NCT06692491)
- Testing
- Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- Peking University Shenzhen Hospital
Bladder Cancer
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to…
- Trial name
- NCT05531123
- Testing
- Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line…
- Trial name
- NCT07733180
- Testing
- Tislelizumab, Oxaliplatin, Leucovorin
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Peripheral T Cell Lymphoma, PTCL
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell…
- Conditions
- Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type
- Trial name
- NCT03493451
- Testing
- Tislelizumab
- Where
- 24 sites in Canada, China and 3 more
- Volunteers
- 77 people
- Sponsor
- BeiGene
Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research hotspot in the academic community. In Asia, Siewert type II and type III are the main types of advanced gastric/gastroesophageal…
- Trial name
- NCT04890392
- Testing
- PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unresectable Non-small Cell Lung Cancer
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus…
- Trial name
- NCT06617936
- Testing
- neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hua Zhang
Melanoma
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
In 2014, an estimated 7,000 patients were diagnosed of melanoma in China. It is growing at an annual rate of 3%-5% and approximately 20,000 new cases are reported each year recently.To date, CFDA only approved dacarbazine as…
- Trial name
- NCT05104801
- Testing
- sitravatinib, tislelizumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Small Cell Lung Cancer Extensive Stage
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed…
- Trial name
- NCT06030258
- Testing
- IN10018, Tislelizumab, Carboplatin
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Solid Tumor
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
Main purpose: To evaluate the safety and tolerability of BAT6021 injection in the treatment of locally advanced or metastatic solid tumors with single drug or combined with tislelizumab(anti PD-1 monoclonal antibody); Explore the…
- Trial name
- NCT05120375
- Testing
- BAT6021
- Where
- 3 sites in China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NEOSTART (NCT06673693)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal…
- Trial name
- NCT05211232
- Testing
- Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Metastatic Triple-negative Breast Cancer
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC).
- Trial name
- NCT05746728
- Testing
- Surufatinib, Tislelizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huihua Xiong
Colorectal Cancer
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
The survival of the refractory CRC is dismal and therapy options are limited ，the researchers aim to investigate the efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a…
- Trial name
- NCT06011330
- Testing
- Fruquintinib combined with anti-PD-1 antibodies
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hunan Cancer Hospital
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene